ASCO 2024 | Evaluating JZP898, an IFN-α and pembrolizumab in advanced solid tumors
Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, shares findings from a Phase I, first-in-human study (NCT06108050) of JZP898, a conditionally activated prodrug of interferon alpha (IFN-α), alone or combined with pembrolizumab in patients with advanced or metastatic solid tumors. The study aims to determine the maximum tolerated dose, safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The combination is designed to enhance antitumor effects while minimizing systemic toxicity. Primary endpoints include dose-limiting toxicities and objective response rate, with secondary endpoints covering pharmacokinetics and overall survival. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Castle Biosciences ; IQVIA ; Merck ; Moderna Therapeutics ; Pfizer
Research Funding – AADi ; Alpine Immune Sciences ; Arcus Biosciences ; Arvinas ; Ascentage Pharma Group ; ASCO ; Astellas Pharma ; Aulos Bioscience ; Bayer ; Bicycle Therapeutics ; BioMed Valley Discoveries ; BioNTech ; Bristol-Myers Squibb ; C4 Therapeutics ; Dragonfly Therapeutics ; EMD Serono ; Epizyme ; Erasca, Inc ; Exelixis ; Foghorn Therapeutics ; G1 Therapeutics ; Genentech ; Gilead Sciences ; GlaxoSmithKline ; IDEAYA Biosciences ; Ikena Oncology ; Immvira ; Infinity Pharmaceuticals ; Jacobio ; Kechow Pharma ; Kezar Life Sciences ; Kinnate Biopharma ; MedImmune ; Mereo BioPharma ; Metabomed ; Moderna Therapeutics ; NBE Therapeutics ; Nektar ; Novartis ; NucMito Pharmaceuticals ; OncoC4 ; Oncorus ; OnKure ; PACT Pharma ; Pfizer ; Plexxikon ; Poseida ; Prelude Therapeutics ; Pyramid Biosciences ; Regeneron ; Sapience Therapeutics ; Scholar Rock ; Seagen ; Synthorx ; Tempest Therapeutics ; TeneoBio ; Tizona Therapeutics, Inc. ; Tmunity Therapeutics, Inc. ; Top Alliance BioScience ; Xilio Therapeutics
